We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $624M
1-Year Est. Return 250.2%
This Fund
S&P 500
This Quarter Est. Return
+13.95%
1 Year Est. Return
+250.2%
3 Year Est. Return
+491.63%
5 Year Est. Return
+985.37%
10 Year Est. Return
–
AUM
$1.96B
AUM Growth
-$393M
Cap. Flow
-$554M
Cap. Flow %
-28.28%
Top 10 Hldgs %
32.05%
Holding
103
New
18
Increased
14
Reduced
37
Closed
22

Top Buys

Rank Stock Value
1
UNH icon
UnitedHealth
UNH
+$49.4M
2
HUM icon
Humana
HUM
+$46.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$26.7M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$26.1M
5
ORKA
Oruka Therapeutics
ORKA
+$24.6M

Top Sells

Rank Stock Value
1
CI icon
Cigna
CI
+$61M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$53.9M
3
REGN icon
Regeneron Pharmaceuticals
REGN
+$50.4M
4
AVTR icon
Avantor
AVTR
+$45.4M
5
ISRG icon
Intuitive Surgical
ISRG
+$45.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
1
Boston Scientific
BSX
$67.9B
$80.6M 4.11%
962,000
-208,100
-18% -$16.4M
DNTH icon
2
Dianthus Therapeutics
DNTH
$5.92B
$79.9M 4.07%
2,917,231
– –
ISRG icon
3
Intuitive Surgical
ISRG
$132B
$72.8M 3.71%
148,200
-96,800
-40% -$45.1M
NTRA icon
4
Natera
NTRA
$47B
$70.6M 3.6%
556,400
-210,100
-27% -$24.1M
CGON icon
5
CG Oncology
CGON
$6.59B
$62.5M 3.19%
1,656,000
+359,775
+28% +$12.6M
ACHC icon
6
Acadia Healthcare
ACHC
$2.66B
$62.5M 3.19%
985,000
-135,000
-12% -$9.75M
NBIX icon
7
Neurocrine Biosciences
NBIX
$15.7B
$53M 2.7%
460,000
-31,000
-6% -$4.25M
UNH icon
8
UnitedHealth
UNH
$353B
$51.1M 2.61%
+87,400
New +$49.4M
JAZZ icon
9
Jazz Pharmaceuticals
JAZZ
$15.9B
$48M 2.45%
431,000
-113,500
-21% -$12.4M
SNDX icon
10
Syndax Pharmaceuticals
SNDX
$1.74B
$47.3M 2.41%
2,455,000
-880,000
-26% -$18.2M
CATX icon
11
Perspective Therapeutics
CATX
$355M
$46M 2.35%
3,444,002
+406,334
+13% +$5.4M
GKOS icon
12
Glaukos
GKOS
$10.6B
$44.9M 2.29%
344,900
+120,900
+54% +$15M
IDYA icon
13
IDEAYA Biosciences
IDYA
$3.87B
$43.5M 2.22%
1,373,000
+256,000
+23% +$9.71M
INSM icon
14
Insmed
INSM
$25.9B
$43.2M 2.2%
592,000
+162,000
+38% +$12M
TMO icon
15
Thermo Fisher Scientific
TMO
$230B
$42.4M 2.16%
68,600
-11,400
-14% -$6.75M
THC icon
16
Tenet Healthcare
THC
$21.5B
$42M 2.15%
253,000
-119,000
-32% -$18M
RARE icon
17
Ultragenyx Pharmaceutical
RARE
$2.52B
$41.8M 2.13%
752,000
-208,000
-22% -$10.6M
HUM icon
18
Humana
HUM
$46.3B
$41.1M 2.1%
+129,700
New +$46.2M
EXAS
19
DELISTED
Exact Sciences
EXAS
$40.1M 2.04%
588,000
+249,500
+74% +$14.1M
ILMN icon
20
Illumina
ILMN
$32.6B
$38.1M 1.94%
292,000
-186,000
-39% -$22.9M
ARVN icon
21
Arvinas
ARVN
$600M
$36.9M 1.88%
1,497,000
-1,490,845
-50% -$38.9M
RVMD icon
22
Revolution Medicines
RVMD
$44.6B
$35.8M 1.83%
790,000
+35,000
+5% +$1.52M
CNTA
23
DELISTED
Centessa Pharmaceuticals
CNTA
$34.1M 1.74%
+2,132,000
New +$26.1M
PHAT icon
24
Phathom Pharmaceuticals
PHAT
$743M
$32.6M 1.66%
1,804,493
+184,493
+11% +$2.58M
XENE icon
25
Xenon Pharmaceuticals
XENE
$5.81B
$32.2M 1.64%
818,000
+64,000
+8% +$2.58M
1
2 3 4 5

Similar funds

DCM
Davidson Capital Management Corpus Christi, Texas $624M AUM 29.17% 1-Year Est. Return
SIG
Spinnaker Investment Group Newport Beach, California $624M AUM 17.54% 1-Year Est. Return
PFA
Pettinga Financial Advisors Evansville, Indiana $624M AUM 24.87% 1-Year Est. Return
ANB
Amarillo National Bank Amarillo, Texas $624M AUM 20.28% 1-Year Est. Return
CWM
Chemistry Wealth Management New York $625M AUM 19.32% 1-Year Est. Return
RIP
RAM Investment Partners Bellevue, Washington $625M AUM 16.29% 1-Year Est. Return
TAM
Third Avenue Management New York $625M AUM 48.93% 1-Year Est. Return
B
Bellecapital Zurich, Switzerland $625M AUM 39.69% 1-Year Est. Return

Avidity Partners Management's Q3 2024 Portfolio in Review

As of Q3 2024, Avidity Partners Management held 103 positions worth $1.96B, down 17% from $2.35B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

Avidity Partners Management withdrew a net $554M in Q3 2024, closing 22 positions and reducing 37 holdings. Its most notable exit was Cigna, an estimated $61M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in UnitedHealth worth $51.1M.

  • Avidity Partners Management's largest Q3 2024 buy was UnitedHealth: 87,400 shares worth $51.1M.
  • Avidity Partners Management added most to Oruka Therapeutics in Q3 2024, an estimated $24.6M increase.
  • Avidity Partners Management's biggest Q3 2024 reduction was Avantor, cutting an estimated $45.4M.
  • Avidity Partners Management fully exited Cigna in Q3 2024, selling an estimated $61M.
  • Avidity Partners Management's ten largest holdings make up 32% of its $1.96B portfolio in Q3 2024.
  • Avidity Partners Management opened 18 new positions and closed 22 in Q3 2024.
  • Avidity Partners Management's portfolio value fell 17% quarter-over-quarter to $1.96B.

Based on Avidity Partners Management's 13F filing for Q3 2024, filed 14 Nov 2024.